NEW YORK (GenomeWeb) – Tebu-bio today announced an agreement to offer Toray's 3D-Gene miRNA and mRNA profiling technology to European researchers.
Tokyo-based Toray has been offering the platform in Japan for years, and the deal announced today is part of its plans to expand into Europe by entering into strategic collaborations. France-based Tebu-bio is now certified by Toray to provide the 3D-Gene Platform Expression Profiling Technology as a service in Europe.
Tebu-bio provides services in genomics, proteomics, and cell-based assays, and the agreement allows the firm to offer a full set of services for biomarker discovery directly to researchers in Europe, the company's Marketing Manager Philippe Fixe said in a statement. The 3D-Gene platform complements Tebu-bio's biomarker-based services, such as antibody-based protein profiling, multiplex protein quantification, ELISAs, and qPCR, he added.
According to Toray, the technology can enhance assay sensitivity and reproducibility, allowing researchers to analyze low-abundance miRNA and mRNAs even in degraded samples, including formalin-fixed, paraffin-embedded tissue.
Financial and other terms of the agreement were not disclosed.